OncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a research report report published on Tuesday morning. The brokerage issued a sell rating on the stock.

A number of other research firms also recently weighed in on OCX. Needham & Company LLC restated a buy rating and issued a $4.25 target price on shares of OncoCyte in a research report on Thursday, May 16th. Stephens restated an equal weight rating and issued a $4.00 target price on shares of OncoCyte in a research report on Wednesday, April 17th. Finally, Benchmark restated a speculative buy rating and issued a $5.00 target price on shares of OncoCyte in a research report on Monday, April 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, OncoCyte currently has an average rating of Hold and an average target price of $4.06.

OncoCyte Stock Up 1.1 %

OCX stock opened at $2.76 on Tuesday. OncoCyte has a twelve month low of $2.08 and a twelve month high of $4.86. The stock has a 50-day simple moving average of $2.73 and a two-hundred day simple moving average of $2.96.

OncoCyte (NASDAQ:OCX) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($1.13) EPS for the quarter. OncoCyte had a negative return on equity of 135.45% and a negative net margin of 2,905.14%. The business had revenue of $0.18 million for the quarter. As a group, equities analysts predict that OncoCyte will post -2.58 EPS for the current fiscal year.

Insider Activity

In other OncoCyte news, Director Andrew Arno bought 33,898 shares of OncoCyte stock in a transaction dated Thursday, April 11th. The shares were purchased at an average cost of $2.95 per share, with a total value of $99,999.10. Following the completion of the purchase, the director now owns 69,054 shares of the company’s stock, valued at $203,709.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of OncoCyte stock in a transaction dated Thursday, April 11th. The shares were purchased at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the purchase, the insider now owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Andrew Arno bought 33,898 shares of OncoCyte stock in a transaction dated Thursday, April 11th. The shares were acquired at an average cost of $2.95 per share, for a total transaction of $99,999.10. Following the completion of the purchase, the director now directly owns 69,054 shares of the company’s stock, valued at approximately $203,709.30. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 2,457,288 shares of company stock valued at $7,176,400. Company insiders own 1.94% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.